Prohibit disadvantaging insurance and Medicaid coverage for nonopioid drugs

Nebraska's LB 252 prohibits Medicaid and commercial insurers from disadvantaging nonopioid pain medications approved by the FDA. It requires that such drugs receive equal coverage terms compared to opioid alternatives, banning higher cost-sharing tiers, stricter prior authorization, or step therapy requirements for nonopioid drugs. The law applies immediately upon FDA approval for pain treatment and mandates exceptions for providers who confirm nonopioid drugs are appropriate for a patient. This directly affects insurers (including Medicaid managed care organizations), healthcare providers, and patients seeking pain management options. The bill aims to ensure equal access to nonopioid treatments without restricting prescribers' choices.